Abstract:Abstract Background Microglia have been implicated in the pathophysiology of Alzheimer’s disease (AD) for over 100 years, and substantial progress has been made in characterizing microglial heterogeneities and biology, including disease‐associated microglia (or DAM, amyloid‐pathology related, neuro‐protective), tau microglia (tau‐pathology related), and inflammatory microglia (neuro‐toxic). However, the crucial next step knowing how to apply these findings to develop new treatments for AD, through uncovering the functional roles and molecular drivers of each microglial subtype, has not yet been accomplished. Method In this study, we conducted single‐cell RNA‐sequencing data integration analyses of ∼0.8 million cells/nuclei by leveraging frozen brain samples from AD subjects across different brain regions from The Alzheimer’s Cell Atlas ( https://taca.lerner.ccf.org/ ) using a deep learning analytic approach. We annotated three microglial subtypes (including DAM, tau, and inflammatory microglia) using well‐established marker genes and then used a human protein‐protein interactome network‐based approach to identify potential molecular drivers of different microglial subtypes across the spectrum of AD. We also applied transition gene network analysis to characterize microglial subtype transition from non‐disease associated to disease‐associated stages at transcriptomic levels. Result Via trajectory analysis we pinpointed the existence of three microglial subtypes across AD progression. We also identified that tau microglia were significantly associated with synaptic processes. Compared to DAM, upregulated genes within inflammatory microglia were more significantly enriched within key immune pathways (e.g., NF‐kappa B and toll‐like receptor signaling pathways). In addition, transition gene networks of inflammatory microglia and DAM were found to contain potential AD pathobiology regulators (e.g., SYK, LYN, IRF8, and CSF1R) and genetic risk genes (including INPP5D, PICALM, and MEF2A). We further conducted network‐based drug repurposing prediction by simultaneously activating DAM while inhibiting inflammatory microglia, which indicated that several predicted repurposable drugs (i.e., fluticasone and mometasone) are significantly associated with reduced risk of AD in large patient databases. Conclusion This study identifies potential underlying mechanisms of microglial subtypes involved in human AD brains, leading to potential drug targets for future development of microglia‐targeted therapies for AD.

S-BEAM: A Semi-Supervised Ensemble Approach to Rank Potential Causal Variants and Their Target Genes in Microglia for Alzheimer’s Disease

Genome-wide prediction and integrative functional characterization of Alzheimer’s disease-associated genes

Identification of immune microenvironment subtypes and signature genes for Alzheimer's disease diagnosis and risk prediction based on explainable machine learning

Functional characterization of Alzheimer's disease genetic variants in microglia

GENOME-WIDE INTEGRATION OF ALZHEIMER’S DISEASE GENETICS AND MYELOID CELL GENOMICS IDENTIFIES NOVEL RISK GENES EXPRESSED IN MICROGLIA

Combining machine learning algorithms and single-cell data to study the pathogenesis of Alzheimer’s disease

Microglia Mediate the Occurrence and Development of Alzheimer’s Disease Through Ligand-Receptor Axis Communication

Integration of Alzheimer's Disease Genetics and Myeloid Cell Genomics Identifies Novel Causal Variants, Regulatory Elements, Genes and Pathways

Elucidating Microglial Heterogeneity and Functions in Alzheimer's Disease Using Single-cell Analysis and Convolutional Neural Network Disease Model Construction

Identification of Immune Cells and Key Genes associated with Alzheimer's Disease

Discovery of disease‐associated, tau, and inflammatory microglial subpopulations and molecular drivers in Alzheimer’s disease using network‐based deep learning integration of human brain single‐cell RNA‐sequencing data

Discovery of Genetic Biomarkers for Alzheimer's Disease Using Adaptive Convolutional Neural Networks Ensemble and Genome-Wide Association Studies

Genetic insights into immune mechanisms of Alzheimer's and Parkinson's disease

Integrative analysis reveals key lysosomal genes as potential therapeutic targets in Alzheimer's disease

Brain-wide Genome-Wide Colocalization Study for Integrating Genetics, Transcriptomics and Brain Morphometry in Alzheimer's Disease

G-Protein Signaling in Alzheimer's Disease: Spatial Expression Validation of Semi-Supervised Deep Learning Based Computational Framework

Identification of Alzheimer's disease susceptibility genes by integrating eight human brain single‐cell transcriptomes with genome‐wide association studies

Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes

Comprehensive Analysis of Alzheimer's Disease Biologically Candidate Causal Genes Revealed by Function Association Study with GWAS.

Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems

Integrating Genome-Wide Association Study and Brain Expression Data Highlights Cell Adhesion Molecules and Purine Metabolism in Alzheimer’s Disease